Teva’s Decade-Long Transformation: From Near-Collapse to Biopharma Growth
A decade after a severe financial crisis, Teva Pharmaceutical Industries is completing its turnaround under CEO Richard Francis, transitioning to common stock on the NYSE and advancing its innovative biopharma pipeline.
On the first trading day of 5787, Richard Francis stood on the famous New York Stock Exchange balcony, surrounded by Teva executives, to ring the opening bell for the Israeli pharmaceutical giant. Shifting from American Depositary Shares (ADS) in Tel Aviv to common stock on the NYSE may seem technical, but it carries profound business, financial, and symbolic weight.
Teva 2026 is a far cry from the company that was once Israel's "people's stock" for decades before plunging into the "people's disappointment" in 2016. Back then, within two years and prior to Kare Schultz stepping in as savior and CEO, Teva lost over 80% of its value. Today, the company marks a decade since the severe crisis that threatened its very existence.
Entering US Indices and Attracting Institutional Investors
While Teva has not yet returned to its peak valuation of nearly $70 billion and $21 billion in sales, for the first time in a decade, its future looks promising. Transitioning to common stock trading opens doors for numerous US institutional investors whose bylaws previously barred them from holding ADS. Furthermore, Teva can now be included in major market indices.
As Eli Kalif, Teva's Chief Financial Officer, stated: "There is no reason why Teva shouldn't enter the Russell 1000 index, and if our valuation continues to climb, perhaps even the S&P 500, though technically current rules restrict it to US-incorporated firms. We are receiving mounting inquiries from investors eager to hear Teva's story."
Quadrupling in Value Over Five Years
Over the past five years, Teva shares have surged nearly fourfold—from $10 to $38—with the bulk of the gains achieved during Richard Francis's three-and-a-half-year tenure as CEO. Teva has outperformed major benchmarks, returning 25% since the beginning of 2006, reclaiming its status as Israel's highest-valued corporation (excluding Palo Alto Networks, which is listed in Tel Aviv) with a market capitalization of roughly $45 billion (approx. 140 billion NIS).
Despite this massive valuation leap, Teva is no longer the undisputed darling of Israeli portfolios. Local retail investors now heavily favor banking, energy, defense, and semiconductor stocks. Teva model 2026 occupies a unique niche on the Tel Aviv Stock Exchange: it combines the corporate flair of American pharma with Israeli roots, yet faces stiff competition from a much broader domestic market.
The Pivot to Growth Strategy
Francis recognized Teva's chronic ailment swiftly, drawing on his experience as the former CEO of Sandoz, a fierce rival. Less than six months into his tenure, he unveiled the "Pivot to Growth" strategy. Unlike typical corporate presentations, Francis has relentlessly executed this strategy point by point, earning the market's trust.
The core of the plan is focus. For years, Teva relied heavily on Copaxone, a multiple sclerosis drug that generated massive revenues and exceptional profitability. In hindsight, this cash cow became a curse, allowing successive CEOs to bypass long-term drug development strategies and instead acquire generic businesses to manufacture artificial growth.
Debt Reduction and Upgraded Credit Ratings
Unlike his predecessors who battled staggering debt and legal liabilities—such as the opioid litigation storm that hit right as Kare Schultz took the helm—Francis inherited a stabilized firm. Schultz focused on operational firefighting and debt reduction, cutting costs rigorously.
Today, for the first time in a decade, Teva carries no crushing debt burden, reflected in credit rating upgrades from all major agencies. Teva's bonds now enjoy investment-grade status, enabling the company to raise $4.9 billion recently to refinance old debt at favorable interest rates.
A Robust Portfolio of Innovative Drugs
Beyond generics and biosimilars like Truxima, Herzuma, and Simlandi, Teva is banking heavily on innovative biopharmaceuticals. A standout performer is Austedo, a treatment for tardive dyskinesia projected to hit $2.5 billion in sales by 2027 and peak at $3 billion. Ajovy, a migraine medication, is slated to reach $1 billion in peak sales.
Furthermore, Teva is launching its combination therapy for schizophrenia—comprising Yusyzni and Olanzapine—targeting $2 billion in peak revenue.
"In pharma terms, Teva's valuation is low, leaving substantial room for value creation. The market loves Francis, and the stock could well double within three years," notes a senior capital markets expert.
With experimental compounds like duvakitug for colitis—currently entering Phase 3 trials in partnership with Sanofi—and an IL-15 molecule for vitiligo and celiac disease, Teva is steadily transforming into a premier biopharmaceutical leader.
